Zentalis Pharmaceuticals (NASDAQ:ZNTL) and Alpha Cognition (NASDAQ:ACOG) Head-To-Head Review
by Jessica Moore · The Cerbat GemZentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report) and Alpha Cognition (NASDAQ:ACOG – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.
Profitability
This table compares Zentalis Pharmaceuticals and Alpha Cognition’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zentalis Pharmaceuticals | N/A | -52.77% | -40.55% |
| Alpha Cognition | -202.23% | -55.71% | -43.78% |
Analyst Recommendations
This is a summary of current recommendations and price targets for Zentalis Pharmaceuticals and Alpha Cognition, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zentalis Pharmaceuticals | 1 | 4 | 1 | 1 | 2.29 |
| Alpha Cognition | 0 | 0 | 2 | 0 | 3.00 |
Zentalis Pharmaceuticals presently has a consensus price target of $5.83, indicating a potential upside of 42.62%. Alpha Cognition has a consensus price target of $16.00, indicating a potential upside of 168.91%. Given Alpha Cognition’s stronger consensus rating and higher probable upside, analysts plainly believe Alpha Cognition is more favorable than Zentalis Pharmaceuticals.
Earnings and Valuation
This table compares Zentalis Pharmaceuticals and Alpha Cognition”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zentalis Pharmaceuticals | $67.43 million | 4.30 | -$137.06 million | ($1.90) | -2.15 |
| Alpha Cognition | $10.22 million | 12.68 | -$20.67 million | ($1.16) | -5.13 |
Alpha Cognition has lower revenue, but higher earnings than Zentalis Pharmaceuticals. Alpha Cognition is trading at a lower price-to-earnings ratio than Zentalis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
Zentalis Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500. Comparatively, Alpha Cognition has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500.
Summary
Alpha Cognition beats Zentalis Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
About Alpha Cognition
Alpha Cognition, Inc. is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.